Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047037 | 0.95 | TSHR (0.39) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL2042374 | 0.86 | TSHR (0.37) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL2047035 | 0.81 | TSHR (0.38) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL2043006 | 0.79 | TSHR (0.37) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL2044226 | 0.78 | TSHR (0.38) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL761853 | 0.76 | TSHR (0.65) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL27552938 | 0.76 | TSHR (0.65) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL11523374 | 0.76 | TSHR (0.65) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL29218362 | 0.76 | TSHR (0.65) | TSHRTHRBUSP2ALDH1A1CYP3A4 | |
| SCHEMBL10925276 | 0.74 | TSHR (0.61) | TSHRTHRBUSP2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | EVONIK ROEHM GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | DNMT1, TET1, MGMT | TSHR 2023/4885THRB 2750/4885USP2 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.